Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $54.28 Average PT from Brokerages

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $54.28.

ZLAB has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th. JPMorgan Chase & Co. upped their target price on Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, March 13th. Scotiabank assumed coverage on Zai Lab in a research report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price objective for the company. Wall Street Zen cut shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Finally, Leerink Partners increased their price objective on shares of Zai Lab from $73.00 to $75.00 and gave the stock an "outperform" rating in a research note on Monday.

Zai Lab Stock Performance

Shares of Zai Lab stock traded up $0.32 on Monday, hitting $35.49. The company had a trading volume of 424,232 shares, compared to its average volume of 910,166. Zai Lab has a 1 year low of $16.01 and a 1 year high of $44.34. The stock has a 50 day moving average of $33.62 and a 200-day moving average of $31.22.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.05. The company had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. Equities analysts anticipate that Zai Lab will post -2.58 earnings per share for the current fiscal year.

Insider Transactions at Zai Lab

In other Zai Lab news, insider Frazor Titus Edmondson III sold 1,874 shares of the business's stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $33.11, for a total value of $62,048.14. Following the completion of the transaction, the insider directly owned 30,375 shares in the company, valued at approximately $1,005,716.25. The trade was a 5.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Ying Du sold 50,000 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $28.57, for a total transaction of $1,428,500.00. Following the sale, the chief executive officer directly owned 479,851 shares of the company's stock, valued at approximately $13,709,343.07. The trade was a 9.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 158,826 shares of company stock worth $4,900,539 in the last ninety days. 4.96% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ZLAB. FMR LLC boosted its holdings in Zai Lab by 749.1% in the fourth quarter. FMR LLC now owns 5,475,505 shares of the company's stock worth $143,403,000 after acquiring an additional 4,830,646 shares in the last quarter. RTW Investments LP purchased a new position in shares of Zai Lab in the 4th quarter valued at about $65,714,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Zai Lab by 46,222.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock valued at $77,058,000 after buying an additional 2,127,598 shares in the last quarter. RA Capital Management L.P. acquired a new stake in Zai Lab in the 4th quarter valued at about $33,917,000. Finally, Principal Financial Group Inc. raised its holdings in shares of Zai Lab by 63.6% during the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock worth $104,257,000 after acquiring an additional 1,121,856 shares during the period. Institutional investors own 41.65% of the company's stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.